New scan could spot breast cancer receptors without needle biopsy
NCT ID NCT03212170
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a special PET/MRI scan using a tracer called FFNP can accurately measure progesterone receptors in invasive breast cancer. Twenty-one women with breast tumors at least 1 cm in size took part. The goal was to see if the scan results match the standard lab test done on biopsy tissue, which could lead to a less invasive way to assess hormone receptor status.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin, Madison
Madison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can sound waves replace the scalpel for breast tumors?
- Could a bank of breast cancer samples unlock new treatments?
- Less radiation for breast cancer? a trial tests a smarter, response-based approach
- Proton beam aims to spare healthy tissue after breast cancer surgery
- Can walking flush out hidden toxins? new study tests exercise against PFAS